Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 27 , ISSUE 6 ( June, 2023 ) > List of Articles

Original Article

Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis

Sampada A Patwardhan, Shweta Panchakshari, Ramya Sambasivam, Surabhi Dhupad, Rajeev N Soman, Amrita P Prayag

Keywords : Carbapenems, Carbapenem-resistant enterobacteriaceae, Ceftazidime-avibactam, Gram-negative sepsis, Polymyxin

Citation Information : Patwardhan SA, Panchakshari S, Sambasivam R, Dhupad S, Soman RN, Prayag AP. Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis. Indian J Crit Care Med 2023; 27 (6):444-450.

DOI: 10.5005/jp-journals-10071-24481

License: CC BY-NC 4.0

Published Online: 31-05-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Introduction: Gram-negative sepsis remains one of the most difficult to treat infections in intensive care units (ICUs). Carbapenems are often considered to be robust and reliable options for treating infections due to Gram-negative bacteria. The dominance of carbapenem-resistant enterobacteriaceae (CRE) has emerged as one of the greatest challenges faced by the medical community today. Carbapenem-resistant enterobacteriaceae may be resistant to all beta lactam antimicrobials including carbapenems and often, are even resistant to other classes of drugs. There are limited studies comparing polymyxin-based therapies with ceftazidime-avibactam (CAZ-AVI)-based therapies for treating infections caused by CRE. Methods: A retrospective study comparing outcomes between patients with bacteremia caused by CRE treated with polymyxin-based combination therapy and CAZ-AVI-based therapy (with or without aztreonam). Results: Of total 104 patients, 78 (75%) were in the CAZ-AVI group. There was no significant difference in the underlying comorbidities between the two groups. The incidence of nephrotoxicity was significantly higher in the polymyxin group (p = 0.017). Ceftazidime-avibactam-based therapy was 66% less likely to be associated with day 14 mortality (p = 0.048) and 67% less likely to be associated with day 28 mortality (p = 0.039) as compared with polymyxin-based therapy. Conclusion: Ceftazidime-avibactam-based therapy may be a superior option to polymyxin-based therapy for infections caused by CRE. This can have significant practical applications, in terms of optimizing therapy for the individual patient as well as sparing polymyxins and reducing the use of polymyxins in our hospitals.

  1. Patel G, Bonomo RA. “Stormy waters ahead”: Global emergence of carbapenemases. Front Microbiol 2013;4:48. DOI: 10.3389/fmicb.2013.00048.
  2. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis [published correction appears in Lancet. 2022 Oct 1;400(10358):1102]. Lancet 2022;399(10325):629–655. DOI: 10.1016/S0140-6736(21)02724-0.
  3. Lutgring JD, Limbago BM. The problem of carbapenemase-producing-carbapenem-resistant-enterobacteriaceae Detection. J Clin Microbiol 2016;54(3):529–534. DOI: 10.1128/JCM.02771-15.
  4. Martin A, Fahrbach K, Zhao Q, Lodise T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: Results of a systematic literature review and meta-analysis. Open Forum Infect Dis 2018;5(7):ofy150. DOI: 10.1093/ofid/ofy150.
  5. Soman R, Bakthavatchalam YD, Nadarajan A, Dwarakanathan HT, Venkatasubramanian R, Veeraraghavan B. Is it time to move away from polymyxins? Evidence and alternatives. Eur J Clin Microbiol Infect Dis 2021;40(3):461–475. DOI: 10.1007/s10096-020-04053-w.
  6. Veeraraghavan B, Shankar C, Karunasree S, Kumari S, Ravi R, Ralph R. Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience. Pathog Glob Health 2017;111(5):240–246. DOI: 10.1080/20477724.2017.1340128.
  7. Kazi M, Khot R, Shetty A, Rodrigues C. Rapid detection of the commonly encountered carbapenemases (New Delhi metallo-β-lactamase, OXA-48/181) directly from various clinical samples using multiplex real-time polymerase chain reaction assay. Indian J Med Microbiol 2018;36(3):369–375. DOI: 10.4103/ijmm.IJMM_18_324.
  8. Pragasam AK, Veeraraghavan B, Shankar BA, Bakthavatchalam YD, Mathuram A, George B. et al. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from in vitro study. Indian J Med Microbiol 2019;37(1):34–41. DOI: 10.4103/ijmm.IJMM_19_189.
  9. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTRP. aeruginosa) (2022). Accessed June 2022. 2022 [PMC free article] [PubMed].
  10. Annual Report: Antimicrobial Resistance Research and Surveillance Network. Accessed June 2022. 2022.
  11. Soman R, Veeraraghavan B, Hegde A, Jiandani P, Mehta Y, Nagavekar V, et al. Indian consensus on the management of CRE infection in critically ill patients (ICONIC) - India. Expert Rev Anti Infect Ther 2019;17(8):647–660. DOI: 10.1080/14787210.2019.1647103.
  12. Nagvekar V, Shah A, Unadkat VP, Chavan A, Kohil R, Hodgar S, et al. Clinical outcome of patients on ceftazidime-avibactam and combination therapy in carbapenem-resistant enterobacteriaceae. Indian J Crit Care Med 2021;25(7):780–784. DOI: 10.5005/jp-journals-10071-23863.
  13. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Infect Dis 2018;66(2):163–171. DOI: 10.1093/cid/cix783.
  14. Fang J, Li H, Zhang M, Shi G, Liu M, Wang Y, et al. Efficacy of ceftazidime-avibactam versus polymyxin b and risk factors affecting clinical outcomes in patients with carbapenem-resistant. Klebsiella pneumoniae infections a retrospective study. Front Pharmacol 2021;12:780940. DOI: 10.3389/fphar.2021.780940.
  15. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. J Infect Dis 2017;215(suppl_1):S28–S36. DOI: 10.1093/infdis/jiw282.
  16. Guh AY, Bulens SN, Mu Y, Jacob JT, Reno J, Scott J, et al. Epidemiology of carbapenem-resistant enterobacteriaceae in 7 US communities, 2012–2013. JAMA 2015;314(14):1479–1487. DOI: 10.1001/jama.2015.12480.
  17. Perez F, El Chakhtoura NG, Yasmin M, Bonomo RA. Polymyxins: To combine or not to combine? Antibiotics (Basel) 2019;8(2):38. DOI: 10.3390/antibiotics8020038.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.